Can febuxostat be discontinued abruptly?

Can Febuxostat Be Stopped Suddenly?

No, febuxostat should not be stopped suddenly—abrupt discontinuation significantly increases the risk of major adverse cardiovascular events (MACE) and cardiovascular death, particularly within the first 1-6 months after stopping the medication.

Critical Safety Concerns with Abrupt Discontinuation

The most compelling evidence comes from a 2022 analysis of the CARES trial data, which revealed alarming findings about stopping urate-lowering therapy 1:

• MACE increased dramatically after discontinuation: The incidence rate jumped from 3.11 per 100 person-years during treatment to 6.71 after stopping
• Highest risk in the first month: Within 1 month of stopping, MACE risk increased 7.4-fold (HR 7.40; 95% CI 5.38-10.17)
• Sustained elevated risk: Within 6 months, MACE risk remained 5.2-fold higher (HR 5.22; 95% CI 4.26-6.39)
• Cardiovascular death predominates: In the first 6 months after stopping, cardiovascular mortality (45.7%) significantly exceeded non-cardiovascular mortality (27.9%, p=0.0001)

The mechanism appears related to changes in serum uric acid levels—larger increases in uric acid from baseline to discontinuation were significantly associated with higher MACE risk after stopping (HR 1.14; 95% CI 1.04-1.26) 1.

Gout Relapse Risk

Beyond cardiovascular concerns, stopping febuxostat leads to high gout relapse rates 2:

• 36-81% of patients experience gout relapse after discontinuing urate-lowering therapy
• Relapses typically occur 1-4.5 years after stopping
• Lower serum urate levels before discontinuation are associated with lower recurrence risk

Guideline Perspective on Long-Term Therapy

Major guidelines emphasize that urate-lowering therapy should be maintained lifelong once initiated 3:

• Serum uric acid <6 mg/dL should be maintained lifelong 3
• The 2020 ACR guidelines strongly recommend continuing prophylaxis for 3-6 months when starting therapy, with ongoing evaluation 4

While guidelines don't explicitly address discontinuation protocols, the emphasis on lifelong maintenance and the research showing harm from stopping makes clear that febuxostat should not be stopped abruptly.

Clinical Approach If Discontinuation Is Necessary

If febuxostat must be stopped (e.g., due to adverse effects like hepatotoxicity 5):

1. Switch to alternative urate-lowering therapy rather than stopping treatment entirely—allopurinol or a uricosuric agent 3
2. Monitor cardiovascular status closely for at least 6 months after any discontinuation
3. Ensure serum uric acid is at target (<6 mg/dL) before considering any change in therapy
4. Restart anti-inflammatory prophylaxis (colchicine, NSAIDs, or corticosteroids) to prevent flares 4, 3

Common Pitfalls to Avoid

• Don't assume febuxostat can be stopped like other chronic medications—the cardiovascular rebound effect is unique and dangerous
• Don't stop in patients with cardiovascular disease—this population has the highest risk from discontinuation 1, 6
• Don't discontinue without a transition plan—have alternative urate-lowering therapy ready

The evidence strongly supports that febuxostat discontinuation carries significant morbidity and mortality risks that peak in the initial months after stopping, making abrupt cessation inadvisable in clinical practice.